114 related articles for article (PubMed ID: 38919632)
1. Nicotine and fluoxetine alter adolescent dopamine-mediated behaviors via 5-HT
Yuan M; Leslie FM
Front Psychiatry; 2024; 15():1380123. PubMed ID: 38919632
[TBL] [Abstract][Full Text] [Related]
2. Nicotine alters limbic function in adolescent rat by a 5-HT1A receptor mechanism.
Dao JM; McQuown SC; Loughlin SE; Belluzzi JD; Leslie FM
Neuropsychopharmacology; 2011 Jun; 36(7):1319-31. PubMed ID: 21412223
[TBL] [Abstract][Full Text] [Related]
3. Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine.
Freo U; Merico A; Ermani M; Ori C
Brain Res; 2010 Jun; 1335():24-34. PubMed ID: 20381465
[TBL] [Abstract][Full Text] [Related]
4. WAY100635 prevents the changes induced by fluoxetine upon the 5-HT1A receptor functionality.
Castro E; Díaz A; Rodriguez-Gaztelumendi A; Del Olmo E; Pazos A
Neuropharmacology; 2008 Dec; 55(8):1391-6. PubMed ID: 18809415
[TBL] [Abstract][Full Text] [Related]
5. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex.
Dawson LA; Nguyen HQ; Smith DL; Schechter LE
J Psychopharmacol; 2002 Jun; 16(2):145-52. PubMed ID: 12095073
[TBL] [Abstract][Full Text] [Related]
6. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
7. Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats.
Li Q; Levy AD; Cabrera TM; Brownfield MS; Battaglia G; Van de Kar LD
Brain Res; 1993 Dec; 630(1-2):148-56. PubMed ID: 8118681
[TBL] [Abstract][Full Text] [Related]
8. Involvement of serotonin in the modulation of cocaine-induced locomotor activity in the rat.
Herges S; Taylor DA
Pharmacol Biochem Behav; 1998 Mar; 59(3):595-611. PubMed ID: 9512061
[TBL] [Abstract][Full Text] [Related]
9. 5-HT1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats.
Moser PC; Sanger DJ
Eur J Pharmacol; 1999 May; 372(2):127-34. PubMed ID: 10395092
[TBL] [Abstract][Full Text] [Related]
10. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
11. Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat.
Hajós M; Hajós-Korcsok E; Sharp T
Br J Pharmacol; 1999 Apr; 126(8):1741-50. PubMed ID: 10372816
[TBL] [Abstract][Full Text] [Related]
12. The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.
Rasmussen K; Calligaro DO; Czachura JF; Dreshfield-Ahmad LJ; Evans DC; Hemrick-Luecke SK; Kallman MJ; Kendrick WT; Leander JD; Nelson DL; Overshiner CD; Wainscott DB; Wolff MC; Wong DT; Branchek TA; Zgombick JM; Xu YC
J Pharmacol Exp Ther; 2000 Aug; 294(2):688-700. PubMed ID: 10900249
[TBL] [Abstract][Full Text] [Related]
13. Activation of 5-HT
Tavares LRR; Baptista-de-Souza D; Canto-de-Souza A
Neuropharmacology; 2018 Jun; 135():376-385. PubMed ID: 29548885
[TBL] [Abstract][Full Text] [Related]
14. Repeated cocaine exposure inhibits the adrenocorticotropic hormone response to the serotonin releaser d-fenfluramine and the 5-HT1A agonist, 8-OH-DPAT.
Levy AD; Li Q; Van de Kar LD
Neuropharmacology; 1994; 33(3-4):335-42. PubMed ID: 7984271
[TBL] [Abstract][Full Text] [Related]
15. Chronic Fluoxetine Impairs the Effects of 5-HT
Baptista-de-Souza D; Tavares LRR; Furuya-da-Cunha EM; Carneiro de Oliveira PE; Canto-de-Souza L; Nunes-de-Souza RL; Canto-de-Souza A
Front Pharmacol; 2020; 11():260. PubMed ID: 32218734
[TBL] [Abstract][Full Text] [Related]
16. 5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms.
Shimizu S; Mizuguchi Y; Tatara A; Kizu T; Andatsu S; Sobue A; Fujiwara M; Morimoto T; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():86-91. PubMed ID: 23838274
[TBL] [Abstract][Full Text] [Related]
17. Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT1A receptors in rat brain.
Castro M; Diaz A; del Olmo E; Pazos A
Neuropharmacology; 2003 Jan; 44(1):93-101. PubMed ID: 12559126
[TBL] [Abstract][Full Text] [Related]
18. Diabetes attenuates the antidepressant-like effect mediated by the activation of 5-HT1A receptor in the mouse tail suspension test.
Miyata S; Hirano S; Kamei J
Neuropsychopharmacology; 2004 Mar; 29(3):461-9. PubMed ID: 14628002
[TBL] [Abstract][Full Text] [Related]
19. The postnatal 5-HT
Ishikawa C; Shiga T
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug; 78():66-74. PubMed ID: 28483674
[TBL] [Abstract][Full Text] [Related]
20. Effects of 5-HT1A and 5-HT2 receptor agonists on the behavioral and neurochemical consequences of repeated nicotine treatment.
Olausson P; Akesson P; Engel JA; Söderpalm B
Eur J Pharmacol; 2001 May; 420(1):45-54. PubMed ID: 11412838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
